InflammX Therapeutics develops Xiflam™, a once-daily oral small molecule that targets the pathologically open Connexin43 hemichannel to modulate the dysregulated NLRP3 inflammasome pathway. This approach addresses the unmet medical needs in diabetic macular edema, diabetic chronic kidney disease, and intermediate age-related macular degeneration, conditions currently lacking effective treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Diabetic macular edema (DME), diabetic chronic kidney disease (CKD), and intermediate age-related macular degeneration (iAMD) lack effective treatments, leading to significant unmet medical needs. Current treatments for these conditions, such as monthly intravitreal injections, can be invasive, ineffective in many patients, and only treat one eye at a time.
Solution
InflammX Therapeutics is developing Xiflam™, a first-in-class, once-daily oral small molecule designed to modulate the dysregulated NLRP3 inflammasome pathway by targeting the pathologically open Connexin43 (Cx43) hemichannel. By inhibiting the Cx43 hemichannel, Xiflam™ aims to interrupt inflammasome-mediated autoinflammation, addressing the underlying pathology in diseases like DME, CKD, and iAMD. This approach offers a differentiated treatment paradigm with the potential to provide therapeutic effects to both eyes simultaneously, improving outcomes for patients with these blinding diseases. The clinical and scientific literature recognizes the correlations and similarities in the microvascular disease present in DR and CKD, suggesting that Xiflam™ may have a beneficial effect on kidney disease as well as retinal disease.
Target Audience
The primary target audience includes patients with diabetic macular edema (DME), diabetic chronic kidney disease (CKD), and intermediate age-related macular degeneration (iAMD), as well as ophthalmologists and nephrologists treating these conditions.
Features
- Once-daily oral administration of Xiflam™, a small molecule
- Targets the pathologically open Connexin43 (Cx43) hemichannel
- Modulates the dysregulated NLRP3 inflammasome pathway
- Potential for simultaneous treatment of both eyes
- Addresses the underlying autoinflammation in DME, CKD, and iAMD